Please login to the form below

Not currently logged in

EMA to evaluate Roche arthritis drug RoActemra for severe COVID-19

FDA approval has already been granted following positive phase 3 trials

EU flag

The European Medicines Agency (EMA) has started evaluating Roche’s anti-inflammatory medicine RoActemra (tocilizumab) to extend its potential use to hospitalised adult patients with severe COVID-19, who are already receiving treatment with corticosteroids and require extra oxygen or mechanical ventilation (breathing assisted by a machine).

RoActemra has already been approved by the FDA after demonstrating positive results for emergency use in hospitalised COVID-19 patients who needed oxygen in phase 3 clinical trials. The drug cut the risk of death among patients hospitalised with severe COVID-19, shortened the time to recovery and reduced the need for mechanical ventilation.

EMA’s human medicines committee (CHMP) will carry out an accelerated assessment, including results from four large randomised studies to decide whether the extension of indication should be authorised, with the outcome expected in mid-October.

Along with Sanofi's Kevzara, Roche’s Actemra was recommended in the World Health Organization’s updated patient care guidelines as a ‘life-saving’ drug for the treatment of COVID-19 patients.

This is EMA’s latest review of a potential coronavirus treatment, following announcements that it is evaluating an arthritis drug developed by Sweden’s Sobi to treat COVID-19 in adults with pneumonia, and Eli Lilly’s rheumatoid arthritis drug Olumiant to treat hospitalised COVID-19 patients receiving oxygen.

A study of Eli Lilly’s JAK inhibitor Olumiant in combination with Gilead’s antiviral med remdesivir met its primary endpoint in patients hospitalised with COVID-19, with remdesivir remaining the only drug currently authorised to treat COVID-19 in the European Union.

Article by
Bryony Andrews

17th August 2021

From: Regulatory



COVID-19 Updates and Daily News

Featured jobs


Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...
6 critical success factors for flawless execution of a rapid first commercial launch
Annemarie Armstrong, Executive Vice President, US Head of Client Services, shares the key considerations for launching a first commercial product, particularly on a rapid timeline....
Hybrid working: Insights and tips for success
Porterhouse Medical has thrived by embracing a hybrid approach to work. Our article looks at hybrid working and provides some tips for success...